MIC-1/GDF15 in Barrett’s oesophagus and oesophageal adenocarcinoma

Authors:

Abstract
Biomarkers are needed to improve current diagnosis and surveillance strategies for patients with Barrett’s oesophagus (BO) and oesophageal adenocarcinoma (OAC). Macrophage inhibitory cytokine 1/growth differentiation factor 15 (MIC-1/GDF15) tissue and plasma levels have been shown to predict disease progression in other cancer types and was therefore evaluated in BO/OAC. One hundred thirty-eight patients were studied: 45 normal oesophagus (NE), 37 BO, 16 BO with low-grade dysplasia (LGD) and 40 OAC. Median tissue expression of MIC-1/GDF15 mRNA was 25-fold higher in BO and LGD compared to NE (Pvs BO (P=0.039); and 47-fold higher in OAC vs NE (P720 discriminated between the presence of either OAC or LGD vs NE with 94% sensitivity and 71% specificity (ROC AUC 0.86, 95% CI 0.73–0.96; Pvs NE (PP=0.015). High MIC-1/GDF15 plasma levels (1140 pg ml−1) were an independent predictor of poor survival for patients with OAC (HR 3.87, 95% CI 1.01–14.75; P=0.047). Plasma and tissue levels of MIC-1/GDF15 are significantly elevated in patients with BO, LGD and OAC. Plasma MIC-1/GDF15 may have value in diagnosis and monitoring of Barrett’s disease.

This publication has 50 references indexed in Scilit: